PNTG

PENNANT GROUP INC

Healthcare | Small Cap

$0.28

EPS Forecast

$286.2

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-07-20

Pennant Group (PNTG) Q1 2026: Revenue Up 36%, GAAP EPS $0.24; Adjusted EPS $0.32

In a quarter where the organics of home health and hospice care show through, Pennant Group, Inc. delivered a clean line: earnings per share metrics improving on both GAAP and adjusted bases, with revenue cresting above the $285 million mark. For investors tracking EPS, revenue forecast cues, and sector peers, the release offers a noteworthy data point—not a dramatic “earnings surprise,” but a choreography of growth across its segments.

Executive snapshot

The NASDAQ ticker: PNTG. The company reported GAAP diluted EPS of $0.24 for the first quarter of 2026, alongside adjusted diluted EPS of $0.32. Total revenue stood at $285.4 million, up 36.0% year over year, driven by stronger performance across its home health and hospice activities. The quarter also highlighted Consolidated Adjusted EBITDAR of $34.7 million and Consolidated Adjusted EBITDA of $21.7 million, with the Adjusted EBITDA prior to non-controlling interest (NCI) at the same growth cadence.

Key metrics at a glance

  • Total revenue: $285.4 million (+36.0% YoY)
  • GAAP diluted EPS: $0.24
  • Adjusted diluted EPS: $0.32
  • Consolidated Adjusted EBITDAR: $34.7 million
  • Consolidated Adjusted EBITDA: $21.7 million
  • Consolidated Adjusted EBITDA before NCI: $23.5 million (YoY increase)

Segment detail: Home Health and Hospice

Home Health and Hospice Services remained the engine, with first-quarter revenue of $229.1 million, up $69.2 million or 43.3% from the prior year quarter. The press release notes that the Home Health and Hospice segment generated: • Adjusted EBITDAR from operations of $36.8 million (up $9.5 million, ~34.9% YoY) • Segment adjusted EBITDA from operations of $33.6 million (up $8.5 million, ~33.7% YoY) • Total home health admissions of 30,721 (+11,843, +62.7% YoY) • Medicare admissions of 13,303 (up 5,704; +75.1% YoY)

The Senior Living Services segment also posted strength, with revenue of $56.3 million and meaningful occupancy and rate metrics—occupancy averaged 78.6%, and monthly revenue per occupied room was $5,388, up modestly versus the prior year.

Management commentary and near-term signal

The report’s narrative centers on growth across the Pennant ecosystem—home health, hospice, and senior living—underpinned by volume gains, pricing discipline, and operational leverage. The release emphasizes improvements in key profitability metrics alongside top-line expansion, positioning Pennant as a multi-segment platform with a clear growth trajectory.

Notably, the company did not issue a revenue forecast for the upcoming period within this filing, and there is no explicit EPS consensus data in the release. Analysts’ expectations, if any, remain outside the document, leaving investors to gauge momentum from the quarter’s reported numbers rather than a stated forward path. In other words: earnings expectations may come from the street, not the slide deck.

What it portends for Pennant and peers

For Pennant, the quarter signals that scale matters—revenue growth is not just a top-line story but a driver of EBITDA and EBITDAR expansion. The magnitude of increases in home health admissions and Medicare-driven volumes suggests the business is benefiting from demographic tailwinds and perhaps share gains in a competitive care-at-home landscape.

From a sector perspective, the results underscore resilience in home-based care subsegments, while highlighting the sensitivity of profitability to reimbursement dynamics, staffing costs, and wage inflation. For peers, the message is twofold: scale matters for margin leverage, and disciplined execution across admissions and care mix can yield outsized EBITDA improvements even in a year where macro headwinds remain—reimbursement reforms and labor markets are a shared risk.

Financial health and outlook considerations

The quarter’s numbers reinforce a cash-flow friendly profile: EPS growth, EBITDA expansion, and robust revenue expansion. Investors should watch for any guidance updates in subsequent communications that could anchor expectations for revenue trajectory, margin expansion, and capital allocation priorities. The absence of an explicit revenue forecast means near-term guidance will need to be inferred from management commentary, investor days, or subsequent filings.

Takeaways

  • PNTG demonstrates meaningful top-line growth driven by Home Health and Hospice services, with corresponding gains in Adjusted EBITDA and EBITDAR.
  • GAAP EPS of $0.24 and Adjusted EPS of $0.32 reflect progress, even as the release withholds a formal forward guidance or EPS consensus for the next quarter.
  • The firm’s admissions and Medicare mix dynamics point to favorable utilization trends, though sector-wide policy and staffing costs remain critical sensitivities.
  • Analysts and investors will likely look to the next quarterly update or a dedicated outlook to anchor expectations on revenue forecast and earnings trajectory for peers in the space.

Commentary in the style of Matt Levine: a pragmatic read on how the numbers dance—growth with discipline, not fireworks, and a reminder that “earnings surprise” is often a function of guidance as much as results. For PNTG and its sector, the rhythm appears to be consolidation and expansion, with the patient cadence of home-based care beginning to translate into steadier earnings velocity.